Antifungal agents versus placebo for preventing fungal infections in immunocompromised patients

Antifungal agents versus placebo for preventing fungal infections in immunocompromised patients

Cochrane Review 12 SoF Entries

Summary of Findings

Key results and quality assessments using GRADE methodology

Outcome Effect Participants Studies Certainty
Caries increment (surface index d3fs)
0 ppm F toothpaste
-1.86 - - Not assessed
Caries increment (surface index d3mfs)
250 ppm F toothpaste
-1.2 - - Not assessed
Caries increment (tooth index d3mft)
250 ppm F toothpaste
-0.4 - - Not assessed
Proportion of children developing new caries
250 ppm F toothpaste
0.92 - - Not assessed
Proportion developing new caries
440 ppm F toothpaste
0.87 - - Not assessed
Adverse effects of toothpaste
0 ppm F toothpaste
nan - - Not assessed
Caries increment (surface index D3(M)FS)
0 ppm F toothpaste
nan - - Not assessed
Caries increment (tooth index D3(M)FT)
0 ppm F toothpaste
nan - - Not assessed
Caries increment (surface index D3MFS)
0 ppm F toothpaste
-0.53 - - Not assessed
Caries increment (tooth index D3MFT)
0 ppm F toothpaste
-0.46 - - Not assessed
Proportion of adults developing new caries
0 ppm F toothpaste
nan - - Not assessed
nan
nan
nan - - Not assessed
GRADE Certainty of Evidence:
High Very confident in the effect estimate
Moderate Moderately confident in the effect estimate
Low Limited confidence in the effect estimate
Very Low Very little confidence in the effect estimate

Review Information

Review ID: CD007868
Outcomes: 12 assessed

Related Content

Evidence Quality Distribution:
Not assessed: 12